151. Cyclodextrin-based supramolecular nanoparticles break the redox balance in chemodynamic therapy-enhanced chemotherapy
- Author
-
Chengyuan Xing, Huikun Chen, Yupeng Guan, Shiqiang Zhang, Tongyu Tong, Ni Ding, Tingting Luo, Yang Kang, and Jun Pang
- Subjects
Male ,Cyclodextrins ,Metallocenes ,beta-Cyclodextrins ,Glutathione ,Polyethylene Glycols ,Surfaces, Coatings and Films ,Electronic, Optical and Magnetic Materials ,Biomaterials ,Colloid and Surface Chemistry ,Cell Line, Tumor ,Humans ,Nanoparticles ,Methacrylates ,Camptothecin ,Reactive Oxygen Species ,Oxidation-Reduction - Abstract
Drug delivery based on abnormal features of the tumor microenvironment (TME) has attracted considerable interest worldwide. In this study, we proposed an applicable strategy to increase the reactive oxygen species (ROS) and inhibit glutathione (GSH), in an effort to amplify oxidative damage in prostate cancer cells. Specifically, we developed dual-responsive supramolecular self-assembled nanoparticles (NPs) based on polymerized methacrylic acid (MA) and polymerized poly(ethylene glycol) dimethyl acrylate-modified β-cyclodextrin (CD) with ferrocene (Fc)-connected (S) (+)-camptothecin (CPT) (designated as MA-CD/Fc-CPT NPs). The as-prepared negatively charged supramolecular NPs can be taken up by tumor cells successfully owing to their reversible negative-to-positive charge transition capacity at acidic pH. The supramolecular NPs increased ROS generation and decreased GSH to amplify oxidative stress and improve the therapeutic effect of chemotherapy. As expected, MA-CD/Fc-CPT NPs displayed good drug delivery capabilities to tumor cells or tissues. MA-CD/Fc-CPT NPs also inhibited cancer cell proliferation in both the cells and tissues. This result was partially due to increased ROS generation and decreased GSH, which contributed to more pronounced oxidative stress. The as-prepared supramolecular NPs displayed great biosafety to normal tissues. According to our results, negatively charged supramolecular MA-CD/Fc-CPT NPs are well-suited for drug delivery and improved cancer treatment in TMEs.
- Published
- 2022